SETD1A Pharmaceutical composition for preventing or treating anticancer drug resistant breast cancers comprising expression or activity inhibitor of SETD1A as an active ingredient

摘要

The present invention relates to a pharmaceutical composition for the prophylactic or therapeutic treatment of cancer-resistant breast cancer containing, as an active ingredient, an expression or activity inhibitor of SETD1A (SET domain containing 1A), which is one of enzymes for methylating histone H3 lysine position 4 in human cells Specifically, it was confirmed that SETD1A was overexpressed in breast cancer cells compared to normal breast cells. When SETD1A was overexpressed in breast cancer cells and regulated specific gene expression induced by estrogen receptor in breast cancer cells and decreased expression of SETD1A in cells, It was confirmed that the proliferation of breast cancer cell lines was inhibited and cell apoptosis was significantly induced and cell migration was reduced. When tamoxifen was treated with cells and expression of SETD1A was decreased, It was found that the inhibition of cancer cell proliferation, cell suicide induction, and cell migration inhibition were increased In addition, when the expression of SETD1A was inhibited in breast cancer cells having tamoxifen resistance, it was confirmed that cell proliferation was remarkably inhibited. Thus, the composition containing the SETD1A expression or activity inhibitor of the present invention as an active ingredient, For the treatment of / RTI